Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2323]
News [5453]
Articles [134]
Editorials [4]
Conferences [158]
elearning [13]
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in...
Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer ( Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy )
7 Nov 2023
Lung Cancer
Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India
Lung Cancer ( Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India )
6 Nov 2023
2 year recurrence free survival benefit for resectable melanoma treated with...
Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )
2 Nov 2023
Atezolizumab with platinum-based CT and niraparib show no improvement in...
Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra...
Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC ( Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )
31 Oct 2023
PARPi combinations to treat patients with mCRPC
Prof Axel Merseburger, Prof Karim Fizazi, Prof Laura-Maria Krabbe and Prof...
PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Prof Karim Fizazi, Prof Laura-Maria Krabbe and Prof Gerhardt Attard )
25 Oct 2023
Where do we stand with mCRPC?
Dr Neal Shore, Prof Neeraj Agarwal, Dr Pasquale Rescigno and Dr Friederike...
Where do we stand with mCRPC? ( Dr Neal Shore, Prof Neeraj Agarwal, Dr Pasquale Rescigno and Dr Friederike Schlurmann )
25 Oct 2023
Selpercatinib benefit, with or without pembro, in first-line advanced RET...
Dr Herbert Ho Fung Loong - The Chinese University of Hong Kong, Hong Kong
Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC ( Dr Herbert Ho Fung Loong - The Chinese University of Hong Kong, Hong Kong )
23 Oct 2023
ESMO 2023: Latest updates in mRCC
Dr Javier Puente, Dr Laurence Albiges, Prof Viktor Grünwald and Prof Stéphane...
ESMO 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Laurence Albiges, Prof Viktor Grünwald and Prof Stéphane Oudard )
23 Oct 2023
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced...
Dr Mary McCormack - University College Hospital, London, UK
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )
23 Oct 2023
Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS...
Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy
Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer  ( Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy )
23 Oct 2023
Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer
Dr Aditya Bardia - Mass General Cancer Center, Boston, USA
Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )
23 Oct 2023
Enfortumab vedotin plus pembrolizumab improves overall survival for advanced...
Prof Thomas Powles - Barts Cancer Centre, London, UK
Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer ( Prof Thomas Powles - Barts Cancer Centre, London, UK )
22 Oct 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation